A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin) In Stable Cystic Fibrosis Patients.

Trial Profile

A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin) In Stable Cystic Fibrosis Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Adare Pharmaceuticals; Mpex Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of pooled prespecified analysis of MPEX204,MPEX207 and MPEX209 studies presented at the 113th International Conference of the American Thoracic Society.
    • 08 Jan 2013 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2013 Primary endpoint 'Time-to-exacerbation-of-symptoms' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top